Author

F. Aberger

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 4 Organism:mouse· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2

Frequent Co-Authors

R. Moriggl· 4 shared S. Grund-Groeschke· 4 shared C. Sternberg· 3 shared D. P. Elmer· 3 shared A. Risch· 2 shared B. Wingelhofer· 2 shared C. G. Huber· 2 shared D. Neureiter· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

R. Moriggl

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

JUN mediates senescence and immune cell recruitment to prevent prostate cancer progression

T. Redmer, M. Raigel, C. Sternberg, R. Ziegler, C. Probst, D. Lindner, A. Aufinger, T. Limberger, K. Trachtova, P. Kodajova, S. Hoegler, M. Schlederer, S. Stoiber, M. Oberhuber, M. Bolis, , L. Kenner

This study shows JUN suppresses prostate cancer progression by inducing senescence and immune cell recruitment, with JUN depletion accelerating tumor growth.

bioRxiv · Nov 29, 2023 · PreprintCancer Biology

STAT3 restricts prostate cancer metastasis and antiandrogen resistance by controlling LKB1/CREB signaling pathway

J. Pencik, C. Philippe, M. Schlederer, M. Pecoraro, S. Grund-Groeschke, W. J. Li, A. Tracz, I. Heidegger, S. Lagger, K. Trachtova, M. Oberhuber, E. Heitzer, O. Osman, H. A. Neubauer, B. Wingelhofer, , C. McKinney

This study identifies STAT3's role in restricting prostate cancer metastasis and antiandrogen resistance by regulating the LKB1/CREB signaling pathway in mouse models and human patients.

bioRxiv · Aug 25, 2022 · PreprintCancer Biology

The NLRP3/eIF2 axis drives cell cycle progression in acute myeloid leukemia

M. Luciano, C. Blöchl, J. Vetter, L. Urwanisch, T. Neuper, D. P. Elmer, R. Bauer, H.-H. Dang, H. Strandt, D. Neureiter, P. Krenn, S. Tesanovic, S. Rieser, O. Bergsleitner, L. Zell, , J. Horejs-Hoeck

This study shows that inhibiting the NLRP3 inflammasome reduces AML cell proliferation by promoting eIF2 phosphorylation and cell cycle arrest.

bioRxiv · Jun 25, 2021 · PreprintImmunology

Casein kinase 1D encodes a novel drug target in Hedgehog-GLI driven cancers and tumor-initiating cells resistant to SMO inhibition

E. Peer, S. K. Aichberger, F. Vilotic, G. Wolfgang, T. Parigger, S. Grund-Groeschke, D. P. Elmer, F. Rathje, A. Ramspacher, M. Zaja, S. Michel, S. Hamm, F. Aberger

This study identifies CSNK1D as a novel therapeutic target in Hedgehog-GLI driven cancers, showing its inhibition reduces tumor-initiating cell growth in both SMO-sensitive and -resistant settings.

bioRxiv · Jun 17, 2021Cancer Biology

STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pigmentation pathway

A. Swoboda, R. Soukup, K. Kinslechner, B. Wingelhofer, D. Schoerghofer, C. Sternberg, H. Pham, M. Vallianou, J. Horvath, D. Stoiber, L. Kenner, L. Larue, V. Poli, F. Beermann, T. Yokota, , R. Moriggl

This study shows that STAT3 promotes melanoma metastasis by repressing the MITF pigmentation pathway through CEBP induction.

Oncogene · Dec 15, 2020Peer-reviewedCancer Biology

Oncogenic GLI1 and STAT1/3 activation drives immunosuppressive tryptophan/kynurenine metabolism via synergistic induction of IDO1 in skin cancer cells

D. P. Elmer, V. Strobl, G. Stockmaier, H.-H. Dang, M. Wiederstein, D. Licha, A. Strobl, C. Sternberg, S. Tesanovic, S. Grund-Groeschke, W. Gruber, F. Wolff, R. Moriggl, A. Risch, R. Reischl, , F. Aberger

This study identifies IDO1-kynurenine pathway activation as a novel mechanism by which HH-IL6 and GLI-STAT signaling promote immunosuppression in skin cancer, suggesting combination therapy targeting these pathways.

bioRxiv · May 4, 2020 · PreprintCancer Biology

Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity

S. Grund-Groeschke, D. Ortner, A. Szenes-Nagy, N. Zaborsky, R. Weiss, D. Neureiter, M. Wipplinger, A. Risch, P. Hammerl, R. Greil, M. Sibilia, I. K. Gratz, P. Stoitzner, F. Aberger

This study investigates how Hedgehog signaling in skin cancer modulates immune cells and resistance to immunotherapy, identifying potential targets for combination treatments.

bioRxiv · Sep 15, 2019Cancer Biology